US3136753A - Derivatives of cardenolides and bufadienolides - Google Patents

Derivatives of cardenolides and bufadienolides Download PDF

Info

Publication number
US3136753A
US3136753A US176760A US17676062A US3136753A US 3136753 A US3136753 A US 3136753A US 176760 A US176760 A US 176760A US 17676062 A US17676062 A US 17676062A US 3136753 A US3136753 A US 3136753A
Authority
US
United States
Prior art keywords
reaction
cymarin
imino
cardenolides
desoxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US176760A
Inventor
Irmscher Klaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck KGaA
Original Assignee
E Merck AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by E Merck AG filed Critical E Merck AG
Application granted granted Critical
Publication of US3136753A publication Critical patent/US3136753A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J19/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Definitions

  • This invention relates to derivatives of the l9-oxo-cardenolides and 19-oxo-bufadienolides. More particularly it is directed to Schifi bases derived from said oxo-compounds having the following formula:
  • R designates R designates a member of the group consisting of alkyl and hydroxylated alkyl radicals having from 1 to 5 carbon atoms.
  • Said Schifi bases may be derived from the l9-oxo compounds by interaction thereof With primary amines or with Schifi bases of an aliphatic carbonyl compound in accordance with the following equation:
  • X designates H,H or a lower alkylidene radical; and
  • R designates an alkyl, cyclohexyl, aryl or hydroxy alkyl radical, which radical may contain substituents.
  • cardenolides designates steroids which have an OH-group in the 14;?- position and which have as a side chain, an a,fl-unsaturated, S-membered lactone ring.
  • the butadienolides have a 14B-hydroxyl group and as side chain a bis-unsaturated, 6-membered lactone ring.
  • Cardenolide Bntadienolide 23 32 CO 22 23 l 20 24 0 21 O ⁇ 21 HQG H O St St 14 14 OH OH 3,136,753 Patented June 9, 1964 wherein:
  • St* designates the structure consisting of the A, B and C rings constitutings the steroidal structure of Formula I.
  • cardio-glycosides are already known.
  • the natural cardio-glycoside digitoxin based on clinical experience, is absorbed upon oral application.
  • All the cardio-glycosides of good oral activity known heretofore have the great disadvantage, however, that they are removed from the body again only very slowly. In this way, the danger of a cumulation in case of repeated treatment is greatly increased.
  • the action is only very slow.
  • cardio-glycosides of the strophanthin type are, however, only of very weak action when administered per os (strophanthins, convallatoxin about 0-5 cf. W. Kiissner, 10c. cit.), so that this important method of application was heretofore not possible.
  • a solvent there are suitable, for instance, alcohols such as methanol, ethanol or isopropanol; hydrocarbons such as benzene, toluene; ethers, such as tetrahydrofuran or dioxane; chlorinated hydrocarbons such as methylene chloride, chlorform, etc.
  • At least one of these solvents be capable of forming an azeotropically boiling mixture with water so that when the solvent is distilled off, the reaction equilibrium is displaced in the desired direction.
  • the use of strong acids and alkalis should be avoided in the purification. Prolonged action of water can in itself cause hydrolysis of the Schiff bases formed. It is preferable only to remove the solvents from the reaction mixture and to purify the crude product by crystallization. Surprisingly, the glycosides are not split in the reaction.
  • the characteristic band of the aldehyde group in the IR-spectrum is at 1715 cm.
  • the reaction can be applied very generally to all cardenolides and bufadienolides having an aldehyde group attached to the 10 C-atom.
  • Both the aglycones and the corresponding 3-glycosides and esters can be used for the reaction.
  • Preferred starting materials are the 19-oxo-steroids corresponding to the above Formula I, i.e., the steroids in which the group attached at position 10 is -OI'IO Cardio-active 19-oxo-steroids, which can be obtained from plants of the families of Strophanthus, Corchorus or Bowiea are particularly suitable.
  • cardenolides aglycones and glycosides or esters derived from them can be used as starting material: strophanthidin, antiarigenin, adonitoxigenin, sarmentosigenin A, corotoxigenin and cannogenin.
  • bufadienolideaglycones and glycosides or esters derived from them can be used: hellebrigenin, scilliglaucosidin, bovogenin A and bovocryptogenin.
  • radical As glycoside radical, there enter into consideration in principle all monoand oligo-saccharides. Preferred radicals are mono-, diand trisaccharides which are derived from hexoses of the following Formula H:
  • C -sugars of the following types enter into consideration: aldohexoses, such as D-glucose, 6-deoxy-aldohexoses, such as L-rhamnose, D-antiarose, D-allomethylose as well as the corresponding S-O-methylethers, such as L-thevetose, and furthermore, 2,6-bisdesoxy-aldohexoses, such as D-boivinose and D-digitoxose, as well as the 3-O-methylethers derived therefrom, such as D-diginose, D-cymarose and D-sarmentose.
  • aldohexoses such as D-glucose
  • 6-deoxy-aldohexoses such as L-rhamnose, D-antiarose
  • D-allomethylose as well as the corresponding S-O-methylethers, such as L-thevetose
  • glycosides which are formed with other sugars, such as with pentoses like D-arabinose, D-xylose and D-lyxose.
  • glycosides for instance enter into consideration: corchoroside, convallatoxin, helveticoside, desglucocheirotoxin, cymarin, cheirotoxin, k-strophanthin-B, convalloside, k-strophanthoside, sarmentoside A, fl-antiarin, adonitoxin, a-antiarin, gofrusside, stroboside, paulioside, milloside, thevetin A, peruvoside, scilliglaucoside, bovocryptoside, desglucohellebrin, hellebrin and bovoside A.
  • the 3-hydroxyl group of the aglycones can also be esterified.
  • the lower aliphatic carboxylates are preferably used, such as acetates, propionates or butyrates.
  • the 3-hydroxyl group can, however, also be esterified with carboxylic acids which, in addition, contain basic substituents capable of forming salts, such as amino groups. Mention may be made by way of illustration in this connection of the glycine, alanine, serine and valine esters. As salts of these esters, the hydrochlorides enter preferably into consideration.
  • amine components of the reaction there enter into consideration all primary aliphatic, araliphatic and aromatic amines.
  • the following amines are, for instance, particularly suitable: methylamine, ethylamine, n-propylamine, n-butylamine, isopropylamine, isobutylamine, tert.- butylamine, cyclohexylamine, benzylamine, sec.-butylamine, isoamylamine, n-hexylamine, n-octylamine, cetylamine, stearylamine, Z-ethylhexylamine, allylamine, oleylamine, cyclopentenylamine, dicyclohexylmethylamine, dimethylaminopropylamine, 3-stearylaminopropylamine, 1- methyl-Z-oarbethoxyvinylamine, Z-methyl 2 carbethoxy propylarnine, 2-ethyl-2-
  • the Schitf bases of the cardenolides and bufadienolides of the invention by reacting the starting compounds with the Schiff bases on an aliphatic carbonyl compound. In this way, there are obtained the Schiif bases of the cardenolides and bufadienolides, while the carbonyl compound which constituted the precursor of the intermediate Schiff bases used in the reaction is liberated.
  • a Schiff base of a low-boiling carbonyl compound As starting material, there is preferably used a Schiff base of a low-boiling carbonyl compound, since it is then readily possible after the reaction is complete to distill from the reaction mixture the low-boiling carbonyl compound which has been liberated.
  • low boiling carbonyl compounds there enter into consideration particularly, compounds which have a boiling point below C.
  • the carbonyl compound can be distilled off in a simpler and considerably gentler manner than the removal of the water produced in the reaction of a primary amine with the 3-keto-19-oxo-steroids (the starting material). In this way, any possible side reactions are substantially avoided.
  • carbonyl compounds having 2 to 5 C-atoms such as: acetone, diethylketone, di-n-propylketone, methylethylketone and other homologs, as well as formaldehyde, acetaldehyde, propionaldehyde, butyraldehyde and their homologs.
  • the substances of this invention are applied in the form of a 5% alcoholic-aqueous solution applied intraduodenally to female cats narcotized with ether (weight 2 to 4 kg.) Two hours thereafter, the animal is after-titrated with g-strophanthin solution until death, 1 cc. per kilogram of body weight of a solution of 0.1 mg. g-strophanthin in 15 cc. of 0.85% solution of NaCl in 5% aqueous alcohol being introduced every 5 minutes into the Vena femoralis. From the required dose of strophanthin, the percentage of the test substance of cardio-activity after absorption is determined.
  • the new compounds, useful as cardio-ac-tive drugs can be put into all customary pharmaceutical forms, such as tablets, pills, dragees, and suppositories, for use, particularly, in oral application.
  • EH 230 (ethanol) IR-bands at 1775, 1735 and'1655 emf- EXAMPLE 4 19-Des0x0-19- (1 '-Desox0-D-Sorbityl-l -Imin0- Cymarin 4 grams of cymarin are dissolved in 100 cc. of ethanol and then treated with a solution of 1.45 grams D-glu- 6 camine in cc. of methanol and with 50 cc. of toluene. The solvents are slowly distilled off, and finally under reduced pressure to dryness. The residue is recrystallized from ethyl acetate. M.P. 92, A 216 mp,
  • Elfi 262 (ethanol) IR-bands at 1775, 1740 and 1660 cm.-
  • EXAMPLE 12 19-Des0x0-19-(fl-Hydroxyethyl)Jmino-k-Strophzmthin- B
  • grams of k-strophanthin-B are reacted with monoethanolamine.
  • the resultant final product has IR-bands at 1655, 1735 and 1785 (21117 X 217 Ill .0,
  • EXAMPLE 16 19-Des0x0-1 9- (n-Amyl -Imino-k-Strophanthin-fl In a manner similar to Example 10, 2 grams of kstrophanthin-fl are reacted with n-amylamine. There is obtained a product which has IR-bands at 1660, 1735 and 1780 cm A 217m Eli 230 EXAMPLE 17 19-Desox0-19-(fl-Hya'roxyethyl) -Imino-k-Strophanthoside In a manner similar to Example 1, 2.5 grams of kstrophanthoside are reacted with monoethanolamine. The resultant compound has IR-bands at 1655, 1740 and 1785 CIHFI. k 218 my,
  • R is a member of the group consisting of H, acetyl and monovalent radicals of a glycoside selected from the group consisting of mono-, diand tri-saccharides;
  • R is a member of the group consisting of ocH, p-H and 8-011;
  • R R R and R are members of the group consisting of H and OH;
  • R is a member of the group consisting of R is a member of the group consisting of alkyl and hydroxylated alkyl radicals having from 1 to 5 carbon atoms.

Description

United States Patent DERIVATIVES 0F CARDENOLIDES AND BUFADIENOLIDES Klaus Irmscher, Darmstadt, Germany, assignor to E.
Merck Aktiengesellschaft, Darmstadt, Germany, a corporation of Germany No Drawing. Filed Mar. 1, 1962, Ser. No. 176,760 Claims priority, application Germany Mar. 4, 1961 13 Claims. (Cl. 260-2105) This invention relates to derivatives of the l9-oxo-cardenolides and 19-oxo-bufadienolides. More particularly it is directed to Schifi bases derived from said oxo-compounds having the following formula:
R, designates R designates a member of the group consisting of alkyl and hydroxylated alkyl radicals having from 1 to 5 carbon atoms.
Said Schifi bases may be derived from the l9-oxo compounds by interaction thereof With primary amines or with Schifi bases of an aliphatic carbonyl compound in accordance with the following equation:
wherein:
St designates the steroidal structure of Formula I to which the unit CH=N-R is attached at position 10; X designates H,H or a lower alkylidene radical; and R designates an alkyl, cyclohexyl, aryl or hydroxy alkyl radical, which radical may contain substituents.
It is to be understood that the term cardenolides designates steroids which have an OH-group in the 14;?- position and which have as a side chain, an a,fl-unsaturated, S-membered lactone ring. The butadienolides have a 14B-hydroxyl group and as side chain a bis-unsaturated, 6-membered lactone ring.
Cardenolide Bntadienolide 23 32 CO 22 23 l 20 24 =0 21 O \21 HQG H O St St 14 14 OH OH 3,136,753 Patented June 9, 1964 wherein:
St* designates the structure consisting of the A, B and C rings constitutings the steroidal structure of Formula I.
Orally effective cardio-glycosides are already known. Thus, for instance, the natural cardio-glycoside digitoxin, based on clinical experience, is absorbed upon oral application. All the cardio-glycosides of good oral activity known heretofore have the great disadvantage, however, that they are removed from the body again only very slowly. In this way, the danger of a cumulation in case of repeated treatment is greatly increased. Furthermore, in all known orally active cardio-glycosides, the action is only very slow.
For an acute therapy, however, rapid removal from the body, no cumulation and rapid action is necessary. These requirements are met by another group of natural cardioglycosides, namely 19-oxo-compounds, such as k-strophantine-B. Thus the daily decrease of the activity level present in the body is 7% in the case of digitoxin, while it is 40% in the case of strophanthin (cf. W. Kiissner, Archiv der Pharmacie, vol. 294/66, page 137 (1961).
The cardio-glycosides of the strophanthin type are, however, only of very weak action when administered per os (strophanthins, convallatoxin about 0-5 cf. W. Kiissner, 10c. cit.), so that this important method of application was heretofore not possible.
Accordingly, it is among the principal objects of this invention to provide:
Schifi? bases of cardenolides and bufadienolides as well as their 3-glycosides and esters;
Orally active cardio-glycosides of rapid action, rapid removal from the body and low cumulation; and methods for the preparation of said substances.
The methods consist in reacting a steroid of the cardenolide or bufadienolide series having an aldehyde group attached to the 10 C-atom of the steroid structure, with a nitrogen-containing compound of the formula RN=X, in which X is H, H or a lower alkylidene radical and R is an alkyl, cyclohexyl, aryl-, aralkyl or hydroxy alkyl radical, possibly substituted, and isolating the reaction product from the reaction mixture under approximately neutral conditions.
In the conversion of the bufadienolides and cardenolides having an aldehyde group on the 10 C-atom, with a primary amine, only a slight excess of primary amine is used. It is preferred to carry the reaction out in the presence of a solvent or of a solvent mixture. As a solvent, there are suitable, for instance, alcohols such as methanol, ethanol or isopropanol; hydrocarbons such as benzene, toluene; ethers, such as tetrahydrofuran or dioxane; chlorinated hydrocarbons such as methylene chloride, chlorform, etc. It is advisable or preferable that at least one of these solvents be capable of forming an azeotropically boiling mixture with water so that when the solvent is distilled off, the reaction equilibrium is displaced in the desired direction. The use of strong acids and alkalis should be avoided in the purification. Prolonged action of water can in itself cause hydrolysis of the Schiff bases formed. It is preferable only to remove the solvents from the reaction mixture and to purify the crude product by crystallization. Surprisingly, the glycosides are not split in the reaction. The characteristic band of the aldehyde group in the IR-spectrum is at 1715 cm. The reaction can be applied very generally to all cardenolides and bufadienolides having an aldehyde group attached to the 10 C-atom. Both the aglycones and the corresponding 3-glycosides and esters can be used for the reaction. Preferred starting materials are the 19-oxo-steroids corresponding to the above Formula I, i.e., the steroids in which the group attached at position 10 is -OI'IO Cardio-active 19-oxo-steroids, which can be obtained from plants of the families of Strophanthus, Corchorus or Bowiea are particularly suitable.
For example, the following cardenolides, aglycones and glycosides or esters derived from them can be used as starting material: strophanthidin, antiarigenin, adonitoxigenin, sarmentosigenin A, corotoxigenin and cannogenin.
Furthermore, for example, the following bufadienolideaglycones and glycosides or esters derived from them can be used: hellebrigenin, scilliglaucosidin, bovogenin A and bovocryptogenin.
As glycoside radical, there enter into consideration in principle all monoand oligo-saccharides. Preferred radicals are mono-, diand trisaccharides which are derived from hexoses of the following Formula H:
( EEP-R,
HOR;
HOH
HOH
I OH -R; Formula 11 wherein:
R and R designate H or OH; and R designates H or CH Thus, for instance, C -sugars of the following types enter into consideration: aldohexoses, such as D-glucose, 6-deoxy-aldohexoses, such as L-rhamnose, D-antiarose, D-allomethylose as well as the corresponding S-O-methylethers, such as L-thevetose, and furthermore, 2,6-bisdesoxy-aldohexoses, such as D-boivinose and D-digitoxose, as well as the 3-O-methylethers derived therefrom, such as D-diginose, D-cymarose and D-sarmentose.
However, there can also be used glycosides which are formed with other sugars, such as with pentoses like D-arabinose, D-xylose and D-lyxose.
In individual cases, the following glycosides for instance enter into consideration: corchoroside, convallatoxin, helveticoside, desglucocheirotoxin, cymarin, cheirotoxin, k-strophanthin-B, convalloside, k-strophanthoside, sarmentoside A, fl-antiarin, adonitoxin, a-antiarin, gofrusside, stroboside, paulioside, milloside, thevetin A, peruvoside, scilliglaucoside, bovocryptoside, desglucohellebrin, hellebrin and bovoside A.
The 3-hydroxyl group of the aglycones can also be esterified. For the method in accordance with the invention, the lower aliphatic carboxylates are preferably used, such as acetates, propionates or butyrates. The 3-hydroxyl group can, however, also be esterified with carboxylic acids which, in addition, contain basic substituents capable of forming salts, such as amino groups. Mention may be made by way of illustration in this connection of the glycine, alanine, serine and valine esters. As salts of these esters, the hydrochlorides enter preferably into consideration.
As amine components of the reaction, there enter into consideration all primary aliphatic, araliphatic and aromatic amines. The following amines are, for instance, particularly suitable: methylamine, ethylamine, n-propylamine, n-butylamine, isopropylamine, isobutylamine, tert.- butylamine, cyclohexylamine, benzylamine, sec.-butylamine, isoamylamine, n-hexylamine, n-octylamine, cetylamine, stearylamine, Z-ethylhexylamine, allylamine, oleylamine, cyclopentenylamine, dicyclohexylmethylamine, dimethylaminopropylamine, 3-stearylaminopropylamine, 1- methyl-Z-oarbethoxyvinylamine, Z-methyl 2 carbethoxy propylarnine, 2-ethyl-2-carbethoxy-n-butylamine, Z-methyl-2-carbethoxyheptylamine, B-hydroxyethylamine or other lower aliphatic primary amines substituted one or more times by OH, O-alkyl or O-acyl, such as Z-aminopropanol-l; 2-aminobutanol-1; Z-aminopentanol-l; l-aminopropanol-Z; 1-aminobutanol-2; l-aminopentanol-Z, etc.; 3 -aminopropanoll ,4-aminobutanoll; S-aminopentanol- 1, etc.; 2-aminopropanediol-l,3; 2-aminobutanetriol-1,3,4; 2-aminopentanetetrol-1,3,4,5, etc.; l-aminopropane-diol- 2,3; l-aminobutanetriol-2,3,4; l-aminopentanetetraol- 2,3,4,5 (for instance arabamine or D-xylamine); D-glucamine, 3-methoxypropylamine.
Furthermore, it is possible to prepare the Schitf bases of the cardenolides and bufadienolides of the invention by reacting the starting compounds with the Schiff bases on an aliphatic carbonyl compound. In this way, there are obtained the Schiif bases of the cardenolides and bufadienolides, while the carbonyl compound which constituted the precursor of the intermediate Schiff bases used in the reaction is liberated.
In accordance with the invention, particularly good yields are obtained if one does not accept the reaction equilibrium which automatically takes place, but rather removes during the course of the reaction one of the resultant reaction products from the reaction mixture. Thus, practically quantitative yields are obtained if the carbonyl compound which is liberated is distilled off from the reaction mixture. Of course, it is also possible simply to wait until the reaction stops at a given equilibrium and then to separate the reaction mixture by customary methods, for instance by chromatography, crystallization or distillation. The carbonyl compound thereby isolated can finally be converted again into a Schiff base, and serve as new starting material. This reaction can possibly also be carried out continuously.
As a rule, it is advisable to carry out this reaction in the presence of an ordinary inert solvent. There are suitable for this purpose, for instance, benzene, toluene, xylene; or alcohols, such as methanol and ethanol; or chloroform, carbon tetrachloride, dioxane or methylene chloride. The presence of a solvent is, however, not absolutely necessary since the Schiif base used for the reaction can itself act as solvent. The Schilf base used for the reaction can be employed in excess. The reaction, however, proceeds in good yield also when operating with equivalent quantities. Particularly, in such case, it is advantageous to remove the resultant carbonyl compound from the reaction mixture during the course of the reaction.
As starting material, there is preferably used a Schiff base of a low-boiling carbonyl compound, since it is then readily possible after the reaction is complete to distill from the reaction mixture the low-boiling carbonyl compound which has been liberated. As low boiling carbonyl compounds, there enter into consideration particularly, compounds which have a boiling point below C. The carbonyl compound can be distilled off in a simpler and considerably gentler manner than the removal of the water produced in the reaction of a primary amine with the 3-keto-19-oxo-steroids (the starting material). In this way, any possible side reactions are substantially avoided.
As low molecular weight carbonyl compound, there enter into consideration, particularly, carbonyl compounds having 2 to 5 C-atoms, such as: acetone, diethylketone, di-n-propylketone, methylethylketone and other homologs, as well as formaldehyde, acetaldehyde, propionaldehyde, butyraldehyde and their homologs.
These carbonyl compounds give as starting material particularly suitable Schiff bases when reacted with amines of the formula RNH (R has the meaning indicated above), and therefore, for instance, with: methylamine, ethylamine, n-propylamine, n-butylamine, isopropylamine, isobutylamine, tert.-butylamine, cyclohexylamine, sec.- butylamine, isoamylamine, N-hexylamine, n-octylamine, 2-ethylhexylamine, N-hydroxyethylarnine or other lower aliphatic primary amines, substituted once or several times by OH, such as, for instance, Z-aminopropanol-l;
2-aminobutanol-1; Z-aminopentanol-l; 1-aminopropanol-2; 1-aminobutanol-2; l-aminopentanol-Z, etc.; 3-aminopropanol-l; 4-aminobutanol-1; S-aminopentanol-l, etc.; 2- aminopropanediol-1,3; 2-aminobutanetriol-l,3,4; 2-aminopentanetetrol-l,3,4,5, etc.; l-aminopropanediol-2,3; 1- aminobutanetriol-2,3,4; 1-aminopentanetetrol-2,3,4,5 (for instance, L-arabamine or D-xylamine), D-glucamine.-
For pharmacological testing, the substances of this invention are applied in the form of a 5% alcoholic-aqueous solution applied intraduodenally to female cats narcotized with ether (weight 2 to 4 kg.) Two hours thereafter, the animal is after-titrated with g-strophanthin solution until death, 1 cc. per kilogram of body weight of a solution of 0.1 mg. g-strophanthin in 15 cc. of 0.85% solution of NaCl in 5% aqueous alcohol being introduced every 5 minutes into the Vena femoralis. From the required dose of strophanthin, the percentage of the test substance of cardio-activity after absorption is determined.
While, for instance, oximines and acetals of 19-oxocompounds of the cardio-glycosides were entirely inactive per os, the following absorption percentages were determined for the instant Schiff bases:
Percent 19-desoxo-l9-(n-buty1)-imino-cymarin 26.4 19-desoxo-l9-(n-propyl)-imino-cymarin 26.7 l9-desoxo-19-(B-hydroxyethyl)-imino-cymarin 29. 8 19-desoxo-19-(n-amyl)-imino-cymarin 35.4
The new compounds, useful as cardio-ac-tive drugs, can be put into all customary pharmaceutical forms, such as tablets, pills, dragees, and suppositories, for use, particularly, in oral application.
The following are examples in accordance with this invention:
EXAMPLE 1 19-Desoxy-19-(fi-Hydroxyethyl)-Imin0-Cymarin 2.5 grams of cymarin are dissolved in 50 cc. of absolute ethanol and 50 cc. of chloroform, and thentreated with 320 mg. of monoethanolamine and 50 cc. of benzene. Distillation is then slowly elfected and the traces of solvent removed under reduced pressure. The residue crystallizes upon being boiled out with benzene. M.P. 98 C. (decomposition), (u) Z|24 (chloroform). IR-bands at 1650 cmf 1735 cm.- and 1785 cmf EXAMPLE 2 19-Des0x0-19- (fly-Dikydroxy-n-Propyl -Imin-Cymarin under reduced pressure. The residue crystallizes out upon trituration with benzene. M.P. 90 C., A 217-218 m l,
. EH 230 (ethanol) IR-bands at 1775, 1735 and'1655 emf- EXAMPLE 4 19-Des0x0-19- (1 '-Desox0-D-Sorbityl-l -Imin0- Cymarin 4 grams of cymarin are dissolved in 100 cc. of ethanol and then treated with a solution of 1.45 grams D-glu- 6 camine in cc. of methanol and with 50 cc. of toluene. The solvents are slowly distilled off, and finally under reduced pressure to dryness. The residue is recrystallized from ethyl acetate. M.P. 92, A 216 mp,
El? 262 (ethanol) IR-bands at 1775, 1740 and 1 660 cmr EXAMPLE 5 19-Des0x0-19- (Isopropyl -Imin0-Hellebrigenin 370 mg. of hellebrigenin are dissolved in 15 cc. of chloroform and treated with 15 cc. of absolute ethanol and 275 mg. of 2-(iso-propyl)-imino-propane. The solution is slowly concentrated to dryness, using reduced pressure at the end. The residue crystallizes and absorbs in the ultra-violet at 300 mu tta... 1 IR-bands of the C=N-double bond at 1650 cmr EXAMPLE 6 1 9-Des0x0-19- (fl-Hydroxy-n-Propyl) -Imin0-Str0phanthidin-3-A cetate 2.2 grams strophanthidin-B-acetate are dissolved in 50 cc. of absolute ethanol and 50 cc. of chloroform, and then treated with 360 mg. of 1-amino-propanol-2 and 50 cc. of benzene. Distillation is effected slowly and the traces of solvent removed under reduced pressure. 216-218 m mex E1? 250 (ethanol) IR-bands at 1650, 1735 and 1785 cmf EXAMPLE 7 19-Des0x0-19- (,B-Hydroxy-n-Butyl) Jmz'no-k-Strophanthin-fi 7.3 grams k-strophanthin-B are dissolved in 100 cc. of absolute ethanol and treated with 1 gram of l-aminobutanol-2 and 50 cc. of benzene. Concentration is slowly efiected and all the solvents finally removed under reduced pressure. The residue crystallizes upon trituration with benzene. A 216-218 m Elfi 220 (ethanol) IR-bands at 1650, 1735 and 1785 cm.-
EXAMPLE 8 J9-Des0x0-19-(Isobutyl)-lmin0-Convallat0xin 4 grams convallatoxin are treated with 300 cc. of chloroform and 930 mg. of 2-(isobutyl)-imino-propane. Distillation is slowly elfected and the chloroform removed. The residue crystallizes upon trituration with benzene. A 217-218 m El? 230 (ethanol) IR-bands at 1775, 1735 and 1655 cmf EXAMPLE 9 19-Des0x0-19- (fi-Hydroxy-Isopropyl) -Imin0-k-Str0- phanthoside 4.45 grams of k-strophanthoside are dissolved in 50 cc. of ethanol and treated with a solution of 390 mg. of 2- amino-propanol-l in 25 cc. of toluene. The solvents are then slowly distilled oif. The crystalline residue absorbs at A 216 mu,
Elfi 262 (ethanol) IR-bands at 1775, 1740 and 1660 cm.-
EXAMPLE 10 19-Desoxo-19-(n-Amyl) -Imin0-Cymarin 4 grams of cymarin are dissolved in a mixture of 50 cc. absolute ethanol and 50 cc. chloroform and treated with 0.7 grams n-amylarnine as well as 50 cc. of henzene. Distillation is slowly effected, finally under reduced pressure. The residue crystallizes upon trituration in benzene. Melting point 98 (decomposition); )t 218 mu,
E12? 230 (ethanol) 3 +16; IR-bands at 1780, 1740, 1660 and 1625 cm' EXAMPLE 11 19-Des0x0-19-(Is0butyl)-lmino-Cymarin In a manner similar to Example 8, 3 grams of cymarin are reacted with isobutylamine. The resultant product exhibits IR-bands at 1775, 1735 and 1655 cmf A 217 mu,
Eli"... 240
EXAMPLE 12 19-Des0x0-19-(fl-Hydroxyethyl)Jmino-k-Strophzmthin- B In a manner similar to Example 1, grams of k-strophanthin-B are reacted with monoethanolamine. The resultant final product has IR-bands at 1655, 1735 and 1785 (21117 X 217 Ill .0,
In a manner similar to Example 3, 1 gram of k-strophanthin-fi is reacted with n-butylamine. The resultant product has IR-bands at 1655, 1735 and 1775 cmf A 217-218 mg,
tta... 4
EXAMPLE 16 19-Des0x0-1 9- (n-Amyl -Imino-k-Strophanthin-fl In a manner similar to Example 10, 2 grams of kstrophanthin-fl are reacted with n-amylamine. There is obtained a product which has IR-bands at 1660, 1735 and 1780 cm A 217m Eli 230 EXAMPLE 17 19-Desox0-19-(fl-Hya'roxyethyl) -Imino-k-Strophanthoside In a manner similar to Example 1, 2.5 grams of kstrophanthoside are reacted with monoethanolamine. The resultant compound has IR-bands at 1655, 1740 and 1785 CIHFI. k 218 my,
8 EXAMPLE 18 1 9-Des0x0-Z 9- n-Butyl -l m ino-k-S trophanthoside In a manner similar to Example 3, 1 gram of kstrophanthoside is reacted with n-butylamine. The resultant product has IR-bands at 1660, 1735 and 1780 emf. A 217 mu,
Eli... 2 10 It will be observed that the Schiff bases of this invention are readily formed by the interaction of the aforesaid 19-oxo-steroids with the primary amine or the intermediate Schiff base upon the addition of the latter, i.e., the mixing of the two interactants; and that one may proceed immediately slowly to distill off the solvent.
What I claim is:
1. Compounds having the formula:
on R5 (Formula I) wherein:
R is a member of the group consisting of H, acetyl and monovalent radicals of a glycoside selected from the group consisting of mono-, diand tri-saccharides;
R is a member of the group consisting of ocH, p-H and 8-011;
R R R and R are members of the group consisting of H and OH;
R is a member of the group consisting of R is a member of the group consisting of alkyl and hydroxylated alkyl radicals having from 1 to 5 carbon atoms.
2. 19-desoxo-19- (Z-hydroxyethyl) -imino-cymarin.
19-desoxo-19 (n-butyl) -imino-cymarin. 19-desoxo-19-(n-amyl)-imino-cymarin. 19-desoxo-19-(iso-butyl)-imino-cyrnarin.
. 19-desoxo-19-(sec.-butyl)-imino-cymarin.
. 19-desox0-19-(2-hydroxy-n-propyl)-iminocymarin. 19-des0xo-19- (3-hydroxy-n-propyl) -imino-cymarin.
19-desoxo-19-(Z-hydroxyethyl)-imino k strophanthin-[3.
10. 19-desoxo-19-(n-butyl)-imino-k-strophanthin-fl.
11. 19-desoxo-19-(n-amyl)-imino-k-strophanthin-fl.
l2. 19-desoxo-19-(2-hydroxyethyl)-imino-k strophanthoside.
13. 19-desoxo-19-(n-butyl)-imino-k-strophanthoside.
References Cited in the file of this patent Bembry et al.: J. Organic Chem, vol. 25, 1960, pp. 1175-1179.
Steroids by Fieser and Fieser, Reinhold Pub. Co., New York (1959), pages 729 to 731, 736 to 738 and 785.
Organic Chemistry by Fieser and Fieser, Reinhold Pub. Co., New York (1956).

Claims (1)

1. COMPOUNDS HAVING THE FORMULA:
US176760A 1961-03-04 1962-03-01 Derivatives of cardenolides and bufadienolides Expired - Lifetime US3136753A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3136753X 1961-03-04

Publications (1)

Publication Number Publication Date
US3136753A true US3136753A (en) 1964-06-09

Family

ID=8087525

Family Applications (1)

Application Number Title Priority Date Filing Date
US176760A Expired - Lifetime US3136753A (en) 1961-03-04 1962-03-01 Derivatives of cardenolides and bufadienolides

Country Status (1)

Country Link
US (1) US3136753A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3673224A (en) * 1968-12-24 1972-06-27 Novo Terapeutisk Labor As Steroid compounds of the estrane, androstane, pregnane and 19-norpregnane series and the preparation thereof
WO2012075337A2 (en) 2010-12-01 2012-06-07 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3673224A (en) * 1968-12-24 1972-06-27 Novo Terapeutisk Labor As Steroid compounds of the estrane, androstane, pregnane and 19-norpregnane series and the preparation thereof
WO2012075337A2 (en) 2010-12-01 2012-06-07 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy

Similar Documents

Publication Publication Date Title
DE69909633T2 (en) WELL WATER-SOLUBLE TRIPTOLID PRODRUGS
US3079378A (en) Acylated psicofuranosyladenines
US3136753A (en) Derivatives of cardenolides and bufadienolides
US3732203A (en) Process for the preparation of cardenolide-and bufadienolide-3-(glycoside-di-alkyl-orthocarbonates)
US2862925A (en) Derivatives of aldosterone
EP0101659B1 (en) 14-amino-steroid derivatives, process for their preparation and their use in therapy
DE1210813B (en) Process for the preparation of 2beta-amino steroids of the androstane or pregnane series of their salts
US2773058A (en) delta-pregnenes
US3852265A (en) 2{40 ,3{40 -o-lower alkylidene or cyclohexylidene periplorhamnoside compounds
US2742461A (en) Pregnanes and method of preparing the same
US3649620A (en) Aldosterone 21-esters and 1-dehydro analogues
Chandler et al. The digitanols of the root bark of Calotropis procera R. Br
US3451994A (en) 14beta-hydroxy-16beta,21-oxidonorcholan-23-oic acid lactams and derivatives
US3752807A (en) Process for the preparation of novel orally effective cardio active cardenolides
US3145200A (en) Steroido[3.2-c]isoxazoles and preparation thereof
US3345362A (en) Novel pregnenolone acetonides
US3850906A (en) Novel delta4/delta5-dehydrocardenolides as well as process for their preparation
Bernstein et al. Synthesis of 17α-Methyl-4-androstene-3β, 17, β-diol
US3452060A (en) 17-hydroxy-17-(3-oxo-1-propynyl or-propenyl) steroids
US3970646A (en) Halo-steroidal thioketals
US2864839A (en) delta4, 7, 9(11)-pregnatriene-17alpha, 21-diol-3, 20-dione and process therefor
US3462423A (en) Cyano-derivatives of steroids
US3919191A (en) 14,15{62 -Epoxycardenolide- and 14,15{62 -epoxybufadienolide-glycosides and process for their preparation
US3398142A (en) 3beta-substituted-4-pregnenes
Morozowich et al. Prostaglandin Prodrugs II: New Method for Synthesizing Prostaglandin C1-Aliphatic Esters